Inhibition of DYRK1B suppresses inflammation in allergic contact dermatitis model and Th1/Th17 immune response.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 04 2023
29 04 2023
Historique:
received:
11
10
2022
accepted:
26
04
2023
medline:
1
5
2023
pubmed:
30
4
2023
entrez:
29
4
2023
Statut:
epublish
Résumé
Allergic contact dermatitis (ACD) is a type IV hypersensitivity mainly mediated by Th1/Th17 immune response. Topical corticosteroid is currently the first-line treatment for allergic contact dermatitis (ACD) and systemic administration of immunosuppressive drugs are used in patients with severe disseminated cases. However, increased risk of adverse effects has limited their use. Thus, the development of a novel immunosuppressant for ACD with low toxicity is a challenging issue. In this study, we began our study by using a murine contact hypersensitivity (CHS) model of ACD to examine the immunosuppressive effects of DYRK1B inhibition. We found that mice treated with a selective DYRK1B inhibitor show reduced ear inflammation. In addition, a significant reduction of Th1 and Th17 cells in the regional lymph node upon DYRK1B inhibition was observed by FACS analysis. Studies in vitro further revealed that DYRK1B inhibitor does not only suppressed Th1 and Th17 differentiation, but also promotes regulatory T cells (Treg) differentiation. Mechanistically, FOXO1 signaling was enhanced due to the suppression of FOXO1
Identifiants
pubmed: 37120440
doi: 10.1038/s41598-023-34211-x
pii: 10.1038/s41598-023-34211-x
pmc: PMC10148813
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7058Informations de copyright
© 2023. The Author(s).
Références
Cytokine. 2015 Apr;72(2):146-53
pubmed: 25647269
Nat Rev Dis Primers. 2021 May 27;7(1):38
pubmed: 34045488
Gastroenterology. 2007 Apr;132(4):1434-46
pubmed: 17408630
Cancer Res. 2000 Jul 1;60(13):3631-7
pubmed: 10910078
J Immunol. 2007 Jan 1;178(1):605-12
pubmed: 17182601
Immunity. 2012 Mar 23;36(3):374-87
pubmed: 22425248
Life Sci. 2018 Jan 15;193:124-131
pubmed: 29158051
Nat Med. 2014 Jan;20(1):62-8
pubmed: 24362934
J Immunol. 2012 Jul 15;189(2):721-31
pubmed: 22675204
J Allergy Clin Immunol. 2009 Oct;124(4):809-18.e2
pubmed: 19541354
BMC Complement Altern Med. 2019 Oct 15;19(1):268
pubmed: 31615568
Immunity. 2016 Jun 21;44(6):1284-98
pubmed: 27332731
Dermatitis. 2019 Jan/Feb;30(1):46-53
pubmed: 30570582
Cancer Biol Ther. 2009 Sep;8(17):1671-9
pubmed: 19633423
Cancer Metastasis Rev. 2020 Sep;39(3):681-709
pubmed: 32372224
Immunity. 2015 Feb 17;42(2):239-251
pubmed: 25692700
J Immunol. 2009 Dec 1;183(11):7169-77
pubmed: 19890056
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1023-32
pubmed: 18787221
J Immunol. 2015 Aug 15;195(4):1791-803
pubmed: 26170390
Cancer Res. 2006 Apr 15;66(8):4149-58
pubmed: 16618736
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6961-6
pubmed: 23569233
Eur J Immunol. 2013 Jul;43(7):1716-26
pubmed: 23620016
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 34855620
J Med Chem. 2015 Mar 26;58(6):2834-44
pubmed: 25738750
Nat Immunol. 2009 Feb;10(2):176-84
pubmed: 19136962
J Clin Invest. 2002 Jan;109(1):131-40
pubmed: 11781358
Nat Rev Immunol. 2012 Sep;12(9):649-61
pubmed: 22918467
Cell Mol Immunol. 2019 Jul;16(7):634-643
pubmed: 30867582
Cell Biochem Biophys. 2006;45(3):303-15
pubmed: 16845176
J Allergy Clin Immunol. 2018 Nov;142(5):1500-1509.e10
pubmed: 29522843
Mol Med Rep. 2016 Jul;14(1):671-80
pubmed: 27221314
Cell Chem Biol. 2022 Sep 15;29(9):1368-1380.e5
pubmed: 35998625
Nature. 2012 Nov 22;491(7425):554-9
pubmed: 23135404
J Clin Invest. 2022 Sep 15;132(18):
pubmed: 36106640
Int J Oncol. 2012 Apr;40(4):1203-9
pubmed: 22159921
J Biol Chem. 2003 Oct 17;278(42):41347-54
pubmed: 12902328
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10885-90
pubmed: 22711815
Cell Mol Life Sci. 2016 Feb;73(4):883-900
pubmed: 26346493
Sci Rep. 2017 Jul 25;7(1):6420
pubmed: 28743892
Oncogene. 2008 Apr 7;27(16):2320-36
pubmed: 18391974
J Immunol Res. 2020 Dec 15;2020:8813558
pubmed: 33381606
J Am Acad Dermatol. 2005 Aug;53(2):303-13
pubmed: 16021126
Br J Dermatol. 2009 Dec;161(6):1301-6
pubmed: 19785613
J Immunol. 2001 Mar 15;166(6):3672-7
pubmed: 11238606
Nat Immunol. 2010 Jul;11(7):618-27
pubmed: 20467422
Eur J Immunol. 1996 Apr;26(4):880-5
pubmed: 8625983
Cancer Cell. 2002 Jul;2(1):81-91
pubmed: 12150827
Cancer Res. 2006 May 15;66(10):5143-50
pubmed: 16707437
World J Stem Cells. 2020 Dec 26;12(12):1553-1575
pubmed: 33505600
Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13533-13542
pubmed: 31196960
Immunity. 2010 Dec 14;33(6):890-904
pubmed: 21167754
Nature. 2013 Apr 25;496(7446):513-7
pubmed: 23467085
Hum Pathol. 2017 Aug;66:48-58
pubmed: 28554575
Annu Rev Immunol. 2010;28:445-89
pubmed: 20192806
Ann Allergy Asthma Immunol. 2021 Jan;126(1):32-39
pubmed: 33091591